Wall Street Hedge Funds Turbocharge Bets on Sana Biotechnology—Should You Buy In?
America’s Biotech Revolution Starts in North Carolina: Inside the Roadshow Uniting Innovation, Jobs, and Security
Biotech Boom: North Carolina Lands Billions in Investments and Eyes Global Leadership
TipRanks Users Beware: Accounts Disabled for Suspicious Activity—Here’s What You Need to Know in 2025
Biotech Breakthroughs: Lawmakers Chart Bold Strategies for the Next Wave of Innovation
Pipeline Integrity Engineering Market 2025: AI-Driven Monitoring Spurs 7% CAGR Growth Through 2030
Bidirectional Brain-Computer Interface Market 2025: Surging Demand Drives 28% CAGR Through 2030
Ampacity Monitoring Systems 2025: Power Grid Intelligence Set to Surge 18% CAGR
Bebionic Prosthetic Hands: Advanced Bionic Solutions for Enhanced Dexterity
Flipbook Animation: Unleashing the Magic of Frame-by-Frame Storytelling
Sana Biotechnology faces a legal deadline on May 20, 2025, amid allegations of misleading investors about its financial health and project viability. Investors claim the
Coumarin, traditionally used in perfumes and tobacco, is now a significant asset in biotechnology and medical diagnostics. Its benzopyrone structure allows it to absorb UV
The 2025 Frost & Sullivan China Entrepreneurs Annual Conference celebrated visionary leaders, including Dr. Yuxin Chen, who is revolutionizing antimicrobial therapy. Dr. Chen, as President
Puma Biotechnology reported a revenue decline to $46 million in Q1 2025 due to inventory and prescription shifts. Despite financial setbacks, scientific progress is promising,
Biotechnology contract manufacturing is rapidly transforming, driven by innovations in life-saving therapeutics. CMOs enable pharmaceutical companies to focus on R&D by handling the manufacturing of
Xoted Biotechnology Labs is bringing a biotech revolution to Spartanburg County, South Carolina. The $4.2 million investment aims to transform the region into a hub
Vir Biotechnology faces a financial shortfall, reporting $3.0 million in revenue against an expected $8.6 million, highlighting the biotech industry’s inherent volatility. Despite fiscal challenges,
THIO, a novel compound by MAIA Biotechnology, targets Non-Small Cell Lung Cancer (NSCLC) by disrupting the telomerase function in cancer cells. THIO integrates into telomeric
Minos Biosciences, based in Paris, addresses the challenges of drug discovery and disease understanding with their innovative platform, MinoSuite™. MinoSuite™ utilizes CAGE-tag™ microfluidic technology, providing
BlackRock strategically reduced its stake in Vir Biotechnology, selling over 1.5 million shares at $6.48 each, maintaining a holding of just over 10.80%. This move
